

Int'l. Appln. No.: PCT/EP00/08728
Docket No. B45197

22. A vaccine composition according to claim 21 in which the preferential stimulator of TH1-cell response is 3D-MPL.

23. A vaccine composition according to claim 19 in which the Hepatitis B antigen is hepatitis B surface antigen.

24. A vaccine composition according to claim 19 which comprises at least one HPV antigen selected from the group consisting of L1, L2, E6 and E7, optionally in the form of a fusion protein or a truncate.

AI
cont'd 25. A vaccine composition according to claim 19 in which an EBV antigen is additionally present.

26. A vaccine composition as defined in claim 25 in which the EBV antigen is gp 350.

27. A vaccine composition according to claim 19 in which a hepatitis A antigen (HAV) is additionally present.

28. A vaccine composition according to claim 25 in which a hepatitis A antigen (HAV) is additionally present.

29. A vaccine composition according to claim 27 in which the HAV antigen is derived from the HM-175 strain.

30. A vaccine composition according to claim 28 in which the HAV antigen is derived from the HM-175 strain.

31. A vaccine composition according to claim 19 in which the carrier is selected from the group comprising aluminum hydroxide, aluminum phosphate and tocopherol and an oil in water emulsion.

Int'l. Appln. No.: PCT/EP00/08728

Docket No. B45197

32. A vaccine composition according to claim 19 which additionally comprises a VZV antigen.

33. A vaccine composition according to claim 25 which additionally comprises a VZV antigen.

34. A vaccine composition according to claim 27 which additionally comprises a VZV antigen.

AI
cont'd 35. A vaccine composition according to claim 32 in which the VZV antigen is gpI.

36. A vaccine composition according to claim 33 in which the VZV antigen is gpI.

37. A vaccine composition according to claim 34 in which the VZV antigen is gpI.

38. A vaccine composition according to claim 19 which additionally comprises a HCMV antigen.

39. A vaccine composition according to claim 25 which additionally comprises a HCMV antigen.

40. A vaccine composition according to claim 27 which additionally comprises a HCMV antigen.

41. A vaccine composition according to claim 35 which additionally comprises a HCMV antigen.

42. A vaccine composition according to claim 38 in which the HCMV antigen is gB685** or pp65.

43. A vaccine composition according to claim 39 in which the HCMV antigen is gB685** or pp65.

Int'l. Appln. No.: PCT/EP00/08728
Docket No. B45197

44. A vaccine composition according to claim 40 in which the HCMV antigen is gB685** or pp65.

45. A vaccine composition according to claim 41 in which the HCMV antigen is gB685** or pp65.

AI
could
46. A vaccine composition according to claim 19 which additionally comprises a *Toxoplasma gondii* antigen.

47. A vaccine composition according to claim 25 which additionally comprises a *Toxoplasma gondii* antigen.

48. A vaccine composition according to claim 27 which additionally comprises a *Toxoplasma gondii* antigen.

49. A vaccine composition according to claim 35 which additionally comprises a *Toxoplasma gondii* antigen.

50. A vaccine composition according to claim 38 which additionally comprises a *Toxoplasma gondii* antigen.

51. A vaccine composition according to claim 46 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

52. A vaccine composition according to claim 47 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

53. A vaccine composition according to claim 48 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.